Catalent and Valerius to collaborate on manufacture of specialty biosimilars14 May 2018
Project will use Catalent’s proprietary GPEx technology, which creates high-performance, highly stable production cell lines in a wide variety of mammalian host cells.
Catalent Pharma Solutions and Valerius Biopharma are to collaborate on the development and manufacture of Valerius’ biosimilar products.
Under the agreement, Catalent Biologics will provide cell line development and support cGMP manufacturing activities from Phase I through to commercial stages at its state-of-the-art biologics manufacturing facility in Madison, Wisconsin.
The project will use Catalent’s proprietary GPEx technology, which creates high-performance, highly stable production cell lines in a wide variety of mammalian host cells. To date, more than 460 different monoclonal antibodies and monoclonal antibody fusions, and over 50 different recombinant proteins have been produced using the GPEx system, achieving large-scale fed-batch production titers of over 7 g/L. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial-scale production.
Valerius Biopharma is a biopharmaceutical company founded to develop biosimilar products as alternatives to high-priced biologics, for indications where there is a substantial medical need. The company has built a research and development hub of scientists and experts with decades of experience in the development of biopharmaceutical and biosimilar compounds, as well as profound clinical and regulatory expertise. The company’s current product pipeline comprises four biosimilar products in different development stages.
“Our business mission is to make the treatment of severe, life-threatening and rare diseases more affordable for patients worldwide by developing biosimilars that meet the highest regulatory standards,” commented Andreas Herrmann, CEO of Valerius. He added: “We selected Catalent as our development and manufacturing partner because of their technical knowledge and expertise in the cGMP manufacture of biosimilars, and proven track record in bringing innovative treatments to market.”
Mike Riley, Vice President and General Manager of Drug Substance and Bioanalytical Services, Catalent Biologics, added: “We are pleased to partner with Valerius on their biologic-based therapeutics for many important indications. We look forward to supporting them in their goal of producing affordable biosimilars that will provide more equal access to medicinal products.”
Opened in April 2013 and recently expanded, Catalent Biologics’ Madison site provides development, manufacturing and analytical services for new biological entities and biosimilars. The facility was designed for flexible cGMP production from 10 L up to 4,000-L scale, and non-GMP production up to 250-L scale and makes extensive use of single-use technologies and unidirectional flow to maximize safety and efficiency. Manufacturing is supported by integrated analytical, process and formulation development capabilities and separate microbiology and quality control functions.
New portable and ready-to-use upper respiratory drug delivery solution
11 Oct 2018
PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.Read more
CPhI Worldwide announces the winners of the 15th Pharma Awards
10 Oct 2018
17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Micro-Sphere increases capsule filling capacity
8 Oct 2018
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.Read more
Symbiosis secures FDA viral vector process approval
5 Oct 2018
Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.Read more
Three-way collaboration to advance gene therapy
4 Oct 2018
Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.Read more
New horizontal flow wrapping machine for hermetic packages
3 Oct 2018
Greater product protection thanks to reliable sealing technologies.Read more
Movement on the market reflected at CPhI Worldwide 2018
3 Oct 2018
Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.Read more
Niche CDMO confirms spray drying for highly potent drugs
1 Oct 2018
Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.Read more
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions
1 Oct 2018
The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation